These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 31184772)
21. [Is it possible to do pharmaco-epidemiological research using electronic databanks in the Swiss health care system?]. Meier ChR Praxis (Bern 1994); 2003 May; 92(21):997-1000. PubMed ID: 12806695 [No Abstract] [Full Text] [Related]
22. Research on drug safety and effectiveness using pharmacoepidemiological databases. Andersen M J Intern Med; 2014 Jun; 275(6):548-50. PubMed ID: 24635741 [No Abstract] [Full Text] [Related]
23. A primer of drug safety surveillance: an industry perspective. Part III: Managing adverse-event data. Allan MC J Pharm Technol; 1992; 8(6):259-73. PubMed ID: 10122649 [TBL] [Abstract][Full Text] [Related]
24. Common Models, Different Approaches. Gagne JJ Drug Saf; 2015 Aug; 38(8):683-6. PubMed ID: 26088718 [No Abstract] [Full Text] [Related]
25. Caveats for the use of operational electronic health record data in comparative effectiveness research. Hersh WR; Weiner MG; Embi PJ; Logan JR; Payne PR; Bernstam EV; Lehmann HP; Hripcsak G; Hartzog TH; Cimino JJ; Saltz JH Med Care; 2013 Aug; 51(8 Suppl 3):S30-7. PubMed ID: 23774517 [TBL] [Abstract][Full Text] [Related]
26. Using predictive analytics and big data to optimize pharmaceutical outcomes. Hernandez I; Zhang Y Am J Health Syst Pharm; 2017 Sep; 74(18):1494-1500. PubMed ID: 28887351 [TBL] [Abstract][Full Text] [Related]
27. Real-World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe. Cave A; Kurz X; Arlett P Clin Pharmacol Ther; 2019 Jul; 106(1):36-39. PubMed ID: 30970161 [No Abstract] [Full Text] [Related]
28. [What place for French morbidity registries in the era of big data?]. Francis F; Terroba C; Persoz C; Gagliolo JM; Alla F Rev Epidemiol Sante Publique; 2020 Apr; 68(2):117-123. PubMed ID: 31974001 [TBL] [Abstract][Full Text] [Related]
29. Big Data Analytics in Medicine and Healthcare. Ristevski B; Chen M J Integr Bioinform; 2018 May; 15(3):. PubMed ID: 29746254 [TBL] [Abstract][Full Text] [Related]
30. Designing a self-administered professional liability claims program for self-insured healthcare entities. Aguilar D; Ireland J J Healthc Risk Manag; 1996; 16(4):41-55. PubMed ID: 10160132 [No Abstract] [Full Text] [Related]
31. Healthcare databases in Europe for studying medicine use and safety during pregnancy. Charlton RA; Neville AJ; Jordan S; Pierini A; Damase-Michel C; Klungsøyr K; Andersen AM; Hansen AV; Gini R; Bos JH; Puccini A; Hurault-Delarue C; Brooks CJ; de Jong-van den Berg LT; de Vries CS Pharmacoepidemiol Drug Saf; 2014 Jun; 23(6):586-94. PubMed ID: 24664855 [TBL] [Abstract][Full Text] [Related]
32. Using 'big data' to validate claims made in the pharmaceutical approval process. Wasser T; Haynes K; Barron J; Cziraky M J Med Econ; 2015; 18(12):1013-9. PubMed ID: 26548546 [TBL] [Abstract][Full Text] [Related]
33. What Does It Take to Transform Real-World Data Into Real-World Evidence? Ramamoorthy A; Huang SM Clin Pharmacol Ther; 2019 Jul; 106(1):10-18. PubMed ID: 31273768 [No Abstract] [Full Text] [Related]
34. A glossary for big data in population and public health: discussion and commentary on terminology and research methods. Fuller D; Buote R; Stanley K J Epidemiol Community Health; 2017 Nov; 71(11):1113-1117. PubMed ID: 28918390 [TBL] [Abstract][Full Text] [Related]
35. Centralized electronic health records benefit emergency medicine. Hoechsmann A CMAJ; 2012 Jan; 184(1):74. PubMed ID: 22232337 [No Abstract] [Full Text] [Related]
36. [Unwanted drug interactions. Keeping up pharmacovigilance using databases]. Schindler B Med Monatsschr Pharm; 2008 Apr; 31(4):155-6. PubMed ID: 18497254 [No Abstract] [Full Text] [Related]
37. The big data revolution: from drug development to better health outcomes? Smith A Am J Manag Care; 2014 May; 20(8 Spec No.):E4. PubMed ID: 25617923 [No Abstract] [Full Text] [Related]
38. The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand? Trifirò G; Gini R; Barone-Adesi F; Beghi E; Cantarutti A; Capuano A; Carnovale C; Clavenna A; Dellagiovanna M; Ferrajolo C; Franchi M; Ingrasciotta Y; Kirchmayer U; Lapi F; Leone R; Leoni O; Lucenteforte E; Moretti U; Mugelli A; Naldi L; Poluzzi E; Rafaniello C; Rea F; Sultana J; Tettamanti M; Traversa G; Vannacci A; Mantovani L; Corrao G Drug Saf; 2019 Mar; 42(3):347-363. PubMed ID: 30269245 [TBL] [Abstract][Full Text] [Related]
39. Active surveillance of postmarket medical product safety in the Federal Partners' Collaboration. Robb MA; Racoosin JA; Worrall C; Chapman S; Coster T; Cunningham FE Med Care; 2012 Nov; 50(11):948-53. PubMed ID: 23047784 [TBL] [Abstract][Full Text] [Related]
40. Challenges of Using ICD-9-CM and ICD-10-CM Codes for Soft-Tissue Sarcoma in Databases for Health Services Research. Hess LM; Zhu YE; Sugihara T; Fang Y; Collins N; Nicol S Perspect Health Inf Manag; 2019; 16(Spring):1a. PubMed ID: 31019431 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]